Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Cash from Operations (2017 - 2025)

Historic Cash from Operations for Protagonist Therapeutics (PTGX) over the last 9 years, with Q3 2025 value amounting to -$1.9 million.

  • Protagonist Therapeutics' Cash from Operations rose 9304.81% to -$1.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $65.5 million, marking a year-over-year decrease of 7157.15%. This contributed to the annual value of $184.2 million for FY2024, which is 36219.03% up from last year.
  • Per Protagonist Therapeutics' latest filing, its Cash from Operations stood at -$1.9 million for Q3 2025, which was up 9304.81% from -$28.8 million recorded in Q2 2025.
  • Protagonist Therapeutics' Cash from Operations' 5-year high stood at $268.6 million during Q2 2024, with a 5-year trough of -$37.7 million in Q1 2022.
  • For the 5-year period, Protagonist Therapeutics' Cash from Operations averaged around -$391578.9, with its median value being -$26.9 million (2021).
  • Within the past 5 years, the most significant YoY rise in Protagonist Therapeutics' Cash from Operations was 112378.99% (2024), while the steepest drop was 27204.01% (2024).
  • Quarter analysis of 5 years shows Protagonist Therapeutics' Cash from Operations stood at -$26.9 million in 2021, then dropped by 17.43% to -$31.6 million in 2022, then soared by 153.61% to $17.0 million in 2023, then plummeted by 272.04% to -$29.2 million in 2024, then surged by 93.36% to -$1.9 million in 2025.
  • Its Cash from Operations stands at -$1.9 million for Q3 2025, versus -$28.8 million for Q2 2025 and $125.4 million for Q1 2025.